DOPF

Last updated
DOPF
DOPF structure.png
Clinical data
Other names2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine
Identifiers
  • 2-[4-(3-fluoropropyl)-2,5-dimethoxyphenyl]ethanamine
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Formula C14H22FNO2
Molar mass 255.333 g·mol−1
3D model (JSmol)
  • COc1cc(CCCF)c(cc1CC(C)N)OC
  • InChI=1S/C14H22FNO2/c1-10(16)7-12-9-13(17-2)11(5-4-6-15)8-14(12)18-3/h8-10H,4-7,16H2,1-3H3
  • Key:UIHSFMYQJAKMHD-UHFFFAOYSA-N

2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine (DOPF) is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (Ki) of 9  nM at the serotonin receptor 5-HT2A but is not known to have been tested in humans. [1]

See also

References

  1. Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion[Phenethylamine From structure to function] (in German). Nachtschatten Verlag AG. p. 778-780. ISBN   978-3-03788-700-4.